ASH abstract shows U.S. study confirms efficacy for Legend’s BCMA CAR T

New data from a U.S. trial of anti-BCMA CAR T therapy JNJ-4528 (LCAR-B38M) from J&J and partner Legend Biotech may calm any lingering concerns that data from a previous trial had been manipulated. The data, along with updated results from bluebird’s next generation BCMA-targeted CAR therapy, are slated for presentation at this year’s American Society of Hematology (ASH) meeting in December.

The U.S. Phase Ib/II CARTITUDE-1 trial showed that in 21 relapsed/refractory multiple myeloma (MM) patients evaluable for efficacy, the overall response rate (ORR) was 91% with four stringent complete responses (sCRs), two complete responses (CRs), seven very good partial responses (VGPRs) and six PRs. The data cutoff was June 24 and included a median follow-up of three months. The trial is enrolling up to 118 patients who have received at least three lines of therapy and is being conducted by Johnson & Johnson (NYSE:JNJ)...